Skip to main content
Retour
A logo

Agilent Technologies, Inc.

Qualité des données : 100%
A
NYSE Healthcare Medical - Diagnostics & Research
114,21 €
▲ 2,19 € (1,96%)
Cap. Boursière : 32,30B
Fourchette du Jour
110,03 € 115,24 €
Fourchette 52 Semaines
96,43 € 160,27 €
Volume
1 074 492
Moyenne 50J / 200J
127,46 € / 129,95 €
Clôture Précédente
112,02 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 24,8 0,3
P/B 4,8 2,9
ROE % 20,6 3,7
Net Margin % 18,8 3,8
Rev Growth 5Y % 2,4 10,0
D/E 0,5 0,2

Objectif de Cours des Analystes

Hold
165,00 € +44.5%
Low: 130,00 € High: 180,00 €
P/E Prévisionnel
18,8
BPA Prévisionnel
5,97 €
Croissance BPA (est.)
+0,0%
CA Est.
7,4 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 8,58 €
8,47 € – 8,69 €
9,3 B 1
FY2029 8,04 €
7,93 € – 8,14 €
8,8 B 1
FY2028 7,29 €
6,75 € – 7,71 €
8,4 B 5

Points Clés

Revenue grew 2,40% annually over 5 years — modest growth
ROE of 20,62% indicates high profitability
Net margin of 18,75% shows strong profitability
Debt/Equity of 0,50 — conservative balance sheet
Generating 1,15B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4,33%

Croissance

Revenue Growth (5Y)
2,40%
Revenue (1Y)6,73%
Earnings (1Y)1,09%
FCF Growth (3Y)-11,59%

Qualité

Return on Equity
20,62%
ROIC10,99%
Net Margin18,75%
Op. Margin21,29%

Sécurité

Debt / Equity
0,50
Current Ratio1,96
Interest Coverage13,21

Valorisation

P/E Ratio
24,79
P/B Ratio4,79
EV/EBITDA22,90
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6,73% Revenue Growth (3Y) 0,84%
Earnings Growth (1Y) 1,09% Earnings Growth (3Y) 2,51%
Revenue Growth (5Y) 2,40% Earnings Growth (5Y) 1,87%
Profitability
Revenue (TTM) 6,95B Net Income (TTM) 1,30B
ROE 20,62% ROA 10,24%
Gross Margin 52,43% Operating Margin 21,29%
Net Margin 18,75% Free Cash Flow (TTM) 1,15B
ROIC 10,99% FCF Growth (3Y) -11,59%
Safety
Debt / Equity 0,50 Current Ratio 1,96
Interest Coverage 13,21 Dividend Yield 0,01%
Valuation
P/E Ratio 24,79 P/B Ratio 4,79
P/S Ratio 4,65 PEG Ratio 9,41
EV/EBITDA 22,90 Dividend Yield 0,01%
Market Cap 32,30B Enterprise Value 33,87B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6,95B 6,51B 6,83B 6,85B 6,32B
Net Income 1,30B 1,29B 1,24B 1,25B 1,21B
EPS (Diluted) 4,57 4,43 4,19 4,18 3,94
Gross Profit 3,64B 3,54B 3,47B 3,72B 3,41B
Operating Income 1,48B 1,49B 1,35B 1,62B 1,35B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 12,73B 11,85B 10,76B 10,53B 10,71B
Total Liabilities 5,99B 5,95B 4,92B 5,23B 5,32B
Shareholders' Equity 6,74B 5,90B 5,85B 5,31B 5,39B
Total Debt 3,35B 3,57B 2,74B 2,77B 2,73B
Cash & Equivalents 1,79B 1,33B 1,59B 1,05B 1,48B
Current Assets 4,59B 3,96B 4,19B 3,78B 3,80B
Current Liabilities 2,35B 1,90B 1,60B 1,86B 1,71B

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#960 of 1052
22

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026